A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.

NCT00042666 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: LY317615

Sponsor

Eli Lilly and Company